tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ASND Stock Latest News

Ascendis Pharma price target raised to $227 from $194 at TD Cowen
The FlyAscendis Pharma price target raised to $227 from $194 at TD Cowen
9h ago
ASND
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
PremiumThe Fly
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
10h ago
ASND
Ascendis Pharma price target raised to $307 from $306 at UBS
PremiumThe Fly
Ascendis Pharma price target raised to $307 from $306 at UBS
10h ago
ASND
Ascendis Pharma price target raised to $290 from $243 at Citi
PremiumThe Fly
Ascendis Pharma price target raised to $290 from $243 at Citi
11h ago
ASND
Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
PremiumThe Fly
Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
11h ago
ASND
Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
PremiumRatingsAscendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
12h ago
ASND
Ascendis Pharma Reports Strong Q2 2025 Growth
Premium
Company Announcements
Ascendis Pharma Reports Strong Q2 2025 Growth
16h ago
ASND
Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
Premium
Ratings
Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
20h ago
ASND
Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
PremiumCompany Announcements
Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
1d ago
6K
ASND
Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year
PremiumThe Fly
Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year
1d ago
ASND
Ascendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies
PremiumCompany Announcements
Ascendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies
1d ago
6K
ASND
Ascendis Pharma’s Clinical Trial Update: Implications for Investors
PremiumCompany Announcements
Ascendis Pharma’s Clinical Trial Update: Implications for Investors
7d ago
ASND
Bullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating
PremiumRatingsBullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating
10d ago
ASND
Buy Rating for Ascendis Pharma Driven by Skytrofa’s FDA Approval and Market Potential
Premium
Ratings
Buy Rating for Ascendis Pharma Driven by Skytrofa’s FDA Approval and Market Potential
11d ago
ASND
Ascendis Pharma Gains FDA Approval for Adult Growth Hormone Therapy
Premium
Company Announcements
Ascendis Pharma Gains FDA Approval for Adult Growth Hormone Therapy
11d ago
6K
ASND
Ascendis Pharma announces FDA approved SKYTROFA
PremiumThe Fly
Ascendis Pharma announces FDA approved SKYTROFA
11d ago
ASND
Ascendis Pharma’s Strong Market Performance and Potential Drive Buy Recommendation
PremiumRatings
Ascendis Pharma’s Strong Market Performance and Potential Drive Buy Recommendation
15d ago
ASND
Ascendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
PremiumRatings
Ascendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
24d ago
ASND
Ascendis Pharma’s Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating
PremiumRatings
Ascendis Pharma’s Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating
25d ago
ASND
Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
PremiumThe FlyAscendis Pharma announces new data from PaTHway Trial at ENDO 2025
25d ago
ASND
Ascendis Pharma’s Cancer Study Termination: Implications for Investors
Premium
Company Announcements
Ascendis Pharma’s Cancer Study Termination: Implications for Investors
28d ago
ASND
Ascendis Pharma price target raised to $243 from $213 at Citi
Premium
The Fly
Ascendis Pharma price target raised to $243 from $213 at Citi
28d ago
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >